SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (189)3/13/2002 10:07:20 AM
From: JOEBT1  Read Replies (1) | Respond to of 508
 
IJ--See my post to you on Yahoo-- should clarify the matter.
messages.yahoo.com
Joe



To: IRWIN JAMES FRANKEL who wrote (189)3/13/2002 12:46:27 PM
From: Michael Young  Respond to of 508
 
In all fairness, I would expect these types of articles under the circumstances. ITMN is getting the vast majority of sales from the off-label IPF indication. The published data in support of the indication consists of a tiny Phase II trial.

There will be plenty of skeptics until until effectiveness is proven in a large Phase III trial.

MIKE


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News